BridgeBio Oncology TherapeuticsBBOT -1.31%12 Return-on-Tangible-Equity is -43.00% as of Mar. 2026. GuruFocus rates BBOT with a GF Score™ of 12/100. Among 1,195 Biotechnology companies, BridgeBio Oncology Therapeutics ranks worse than 72.05% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. BridgeBio Oncology Therapeutics's annualized net income for the quarter that ended in Mar. 2026 was $-168.42 Mil. BridgeBio Oncology Therapeutics's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $391.69 Mil. Therefore, BridgeBio Oncology Therapeutics's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -43.00%.
The historical rank and industry rank for BridgeBio Oncology Therapeutics's Return-on-Tangible-Equity or its related term are showing as below:
BBOT'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -115.33 Med: -115.33 Max: -96.03
Current: -96.03
During the past 3 years, BridgeBio Oncology Therapeutics's highest Return-on-Tangible-Equity was -96.03%. The lowest was -115.33%. And the median was -115.33%.
BBOT's Return-on-Tangible-Equity is ranked worse than 72.05% of 1195
companies
in the Biotechnology industry
Industry Median: -42.21
vs BBOT: -96.03
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
BridgeBio Oncology Therapeutics Return-on-Tangible-Equity Related Terms
BridgeBio Oncology Therapeutics Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BBOT vs FTH, MNPR, MDXG: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, BridgeBio Oncology Therapeutics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BridgeBio Oncology Therapeutics Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BridgeBio Oncology Therapeutics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where BridgeBio Oncology Therapeutics's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -43.00% mean?
BridgeBio Oncology Therapeutics (BBOT) has a Return-on-Tangible-Equity of -43.00% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on BridgeBio Oncology Therapeutics and its competitors. According to the industry distribution chart, BridgeBio Oncology Therapeutics ranks #861 out of 1195 companies in the Biotechnology industry, placing it in the top 72.1%.
Is BridgeBio Oncology Therapeutics' Return-on-Tangible-Equity too high?
BridgeBio Oncology Therapeutics' current Return-on-Tangible-Equity is -43.00%. Based on the distribution chart, BridgeBio Oncology Therapeutics ranks #861 out of 1195 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BridgeBio Oncology Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Oncology Therapeutics' Return-on-Tangible-Equity compare to FTH and MNPR?
According to the Biotechnology industry distribution chart, BridgeBio Oncology Therapeutics ranks #861 out of 1195 companies for Return-on-Tangible-Equity. This places BridgeBio Oncology Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on BridgeBio Oncology Therapeutics and its competitors. BridgeBio Oncology Therapeutics's current Return-on-Tangible-Equity is -43.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Oncology Therapeutics stock overvalued right now?
BridgeBio Oncology Therapeutics (BBOT) has a current Return-on-Tangible-Equity of -43.00%. The current Return-on-Tangible-Equity is -43.00%. BridgeBio Oncology Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For BridgeBio Oncology Therapeutics (BBOT), the current Return-on-Tangible-Equity is -43.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BridgeBio Oncology Therapeutics Business Description
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
12GF Score
Get the complete analysis for BBOT
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BBOT has been successfully added to your 
